Bailard’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bailard’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-24,038	Closed	-$897K	–	782
2021 Q2	$897K	Hold	24,038	–	–	0.03%	286
2021 Q1	$615K	Buy	+24,038	New	+$614K	0.02%	348
2019 Q2	–	Sell	-13,100	Closed	-$192K	–	617
2019 Q1	$192K	Buy	+13,100	New	+$151K	0.01%	495
2018 Q4	–	Sell	-122,500	Closed	-$1.87M	–	578
2018 Q3	$1.87M	Buy	122,500 +72,700	+146%	+$1.06M	0.11%	165
2018 Q2	$610K	Buy	+49,800	New	+$626K	0.04%	311

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bailard's DRNA Position: Q3 2021 in Review

Bailard sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 24,038 shares — an estimated $897K sold.

Bailard first reported a position in DRNA in Q2 2018 and held it in 5 quarters. The position peaked at $1.87M in Q3 2018. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Bailard reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Bailard sold 24,038 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $897K.
Bailard first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2018 and held it in 5 quarters.
Bailard's Dicerna Pharmaceuticals, Inc. position peaked at $1.87M in Q3 2018.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.